---
title: Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome
date: '2024-04-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38643510/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240422180751&v=2.18.0.post9+e462414
source: Blood
description: We investigated efficacy and safety of mavorixafor, an oral CXCR4 antagonist
  for participants with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis
  (WHIM) syndrome, a rare immunodeficiency caused by CXCR4 gain-of-function variants.
  This randomized (1:1), double-blind, placebo-controlled, phase 3 trial enrolled
  participants aged ≥12 years with WHIM syndrome and absolute neutrophil count (ANC)
  ≤400/μL. Participants received once-daily mavorixafor or placebo for 52 weeks. ...
disable_comments: true
---
We investigated efficacy and safety of mavorixafor, an oral CXCR4 antagonist for participants with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, a rare immunodeficiency caused by CXCR4 gain-of-function variants. This randomized (1:1), double-blind, placebo-controlled, phase 3 trial enrolled participants aged ≥12 years with WHIM syndrome and absolute neutrophil count (ANC) ≤400/μL. Participants received once-daily mavorixafor or placebo for 52 weeks. ...